Cervical changes associated with progestagen-only contraceptives: A team approach

Contraception

Volumn 69, Issue 2, 2004, Pages 121-127

  Darwish, A ^a   Labeeb, S ^a,c   Galal, M ^b   Rashad, H ^a,c   Hassan, S ^c  

^a ASSIUT UNIVERSITY   (Egypt)

^b Assiut University   (Egypt)

^c Assiut University   (Egypt)

Author keywords

Colposcopy; Cytology; Injectables; Minipills; Norplant; Nursing

Indexed keywords

COPPER INTRAUTERINE DEVICE; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE;

ADULT; ARTICLE; CANCER RISK; COLPOSCOPY; CONTROLLED STUDY; DEVELOPING COUNTRY; FAMILY PLANNING; FEMALE; HEALTH CENTER; HISTOLOGY; HORMONAL CONTRACEPTION; HUMAN; INTERVIEW; MEDICAL ASSESSMENT; NORMAL HUMAN; NURSE ATTITUDE; NURSING STAFF; PAPANICOLAOU TEST; PATIENT COUNSELING; PATIENT EDUCATION; PROSPECTIVE STUDY; RISK FACTOR; STATISTICAL SIGNIFICANCE; UNIVERSITY HOSPITAL; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CYTOLOGY; UTERUS BIOPSY; VAGINA PESSARY;

EID: 0842346283     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2003.09.010     Document Type: Article

References (32)

1. Cervical cancer control in developing countries memorandum from WHO meeting . Bull WHO. 74:1996;351.
2. Arevian M., Noureddine S., Kabakian T. A survey of knowledge, attitude, and practice of cervical screening among Lebaneesel Avmenian women. Nurs Outlook. 45:1997;17-22.
3. Darwish A., Gadallah H. One-step management of cervical lesions. Int J Gynecol Obstet. 61:1998;261-267.
4. World Health Organization. Oral contraceptives and neoplasia. WHO Technical report series. Geneva: World Health Organization, 1992. p. 12-6.
5. Cartes R.M. Use of injectable contraceptives and cancer risk. Gynaecol Forum. 5:2000;13-15.
6. ACOG technical bulletin: cervical cytology: evaluation and management of abnormalities. Int J Gynecol Obstet 1993;43:212-20.
7. Solomon D., Davey D., Kurman R., et al. The 2001 Bethesda System terminology for reporting results of cervical cytology. The Bethesda 2001 Workshop . JAMA. 287:2002;2114-2119.
8. Anderson M.C., Jordan J.A., Mose A.R., Sharp F. A text and atlas of integrated colposcopy for colposcopists, histopathologists, and cytologists. 1992;Chapman & Hall Med, London.
9. Sherris J. Preventing cervical cancer in low-resource settings. Outlook 1998;1-8. Internet publications. Available at: http://www.guncancer. com/pap-test html. p. 1-15.
10. Lovejoy N.C. Precancerous lesions of the cervix. Personal risk factors. Canc Nurs. 10:1987;2-14.
11. Ries LA, Hamley BF, Miller BA, Hartman AM, Edwards BK. Cancer statistics review 1973-1988. Bethesda (MD): National Cancer Institute, 1991. p. 68-70.
12. Sawaya G.F., Harper C., Balistreri E., Boggess J., Darney P. Cervical neoplasia risk in women provided hormonal contraception without a Pap smear. Contraception. 63:2001;57-60.
13. Misra J.S., Engineer A.D., Das K., Tandon P. Cervical carcinogenesis and contraception. Diagn Cytopathol. 7:1991;346-352.
14. Misra J.S., Engineer A.D., Tandon P. Cervical cytology associated with levonorgstrel contraception. Acta Cytol. 39:1995;45-49.
15. Kaptain S., Bloom L.I., Weir M.M. Hormonal effect of Depo-Provera in cervical smear a comparison with triphasil and postmenopausal effects . Cancer. 25:2002;96. :74-82.
16. Valente P.T., Schantz H.D., Trabal J.F. Cytologic changes in cervical smears associated with prolonged use of depot-medroxyprogesterone acetate. Cancer. 84:1998;328-334.
17. Collaborative study of neoplasia and steroid contraceptive invasive cervical cancer and combined oral contraceptive. BMJ. 290:1986;961-965.
18. ACOG technical bulletin. Hormonal contraception. No. 198, Oct 1994 (replaces no. 106, July 1987). Int J Gynecol Obstet 1995;48:115-26.
19. La Vecchia C. Depot-medroxyprogesterone acetate, other injectable contraceptives, and cervical neoplasia. Contraception. 49:1994;223-230.
20. Kaunitz A.M. Injectable contraception new and existing options . Obstet Gynecol Clin North Am. 27:2000;741-780.
21. Post-marketing surveillance of Norplant contraceptive implants; I. Contraceptive efficacy and reproductive health. Contraception. 63:2001;167-186.
22. Mascarenhas L., vanBeek A., Bennink H.C., Newton J. A 2-year comparative study of endometrial histology and cervical cytology of contraceptive implant users in Birmingham, UK. Hum Rep. 13:1998;3057-3060.
23. Mashburn J., Scharbo-Dehaan M. A clinician's guide to Pap smear interpretation. Nurse Pract. 22:1997;115-130.
24. Bauman B.J. Use of a cervical brush for papanicolaou smear collection. A meta-analysis. J Nurse Midwifery. 38:1995;267-271.
25. Kjaer K.S., Devilliesvs E.M., Dahl Enghdm G., Bock J.E., Vestergard B.F. Risk factors for cervical neoplasia in Denmark. APMIS. 8:(Suppl):1998;1-41.
26. Disaia PJ, Creasman WT. Preinvasive disease of the cervix. In: Clinical gynecologic oncology. St. Louis (MO): Mosby Year Book, 1993.
27. Harlan L.C., Bernstein A.B., Kessler L.G. Cervical cancer screening who is not screened and why? Am J Public Health. 81:1991;885-891.
28. Lovejoy N.C. Precancerous lesions of the cervix. Personal risk factors. Cancer Nurs. 10:1987;2-14.
29. Idestrom M., Milsom I., Andersson-Ellstrom A. Knowledge and attitudes about the Pap smear screening program a population-based study of women aged 20-59 years . Acta Obstet Gynecol Scand. 81:2002;962-967.
30. Redman BK, Thomas SA, McClaskey J. Nursing intervention treatment for nursing diagnosis. Philadelphia: WB Saunders, 1985. p. 160-2.
31. Nugent L.S., Clark R. Colposcopy sensory information for client education . J Obstet Gynecol Neonatal Nurs. 25:1996;225-231.
32. Foulks M.J. The Papanicolaou smear its impact on the promotion of women's Health . J Obstet Gynecol Neonatal Nurs. 27:1998;367-373.